Meta-analysis of 123I-MIBG cardiac scintigraphy for the diagnosis of Lewy body-related disorders

Alisha E. King, Jim Mintz, Donald R Royall

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Patients with parkinsonism pose a diagnostic challenge. Parkinson's disease may be difficult to distinguish from multiple system atrophy and progressive supranuclear palsy, whereas Parkinson's disease and dementia with Lewy bodies can be difficult to distinguish from Alzheimer's disease and other dementias. A number of studies have found diminished cardiac 123I-metaiodobenzylguanidine uptake in Lewy body-related conditions (Parkinson's disease and Lewy body dementia). In 2005, the Dementia With Lewy Bodies Consortium considered 123I-metaiodobenzylguanidine cardiac scintigraphy a "supportive" diagnostic feature, based on limited evidence. We report a meta-analysis of the literature and an assessment of the utility of 123I-metaiodobenzylguanidine for the diagnosis of dementia with Lewy bodies and Parkinson's disease. A search was conducted of articles published between 1950 and June 2010. Forty-six studies involving neuropsychiatric and movement disorders, comprising 2680 subjects, were included in the analysis. A mixed-effects regression model was used to analyze the delayed mean heart-to-mediastinum ratio of 123I-metaiodobenzylguanidine uptake. 123I-metaiodobenzylguanidine cardiac scintigraphy sensitively detected and specifically distinguished 2 diagnostic clusters: (1) Parkinson's disease, dementia with Lewy bodies, and rapid eye movement sleep behavior disorder; and (2) normal controls and patients with Alzheimer's disease, multiple system atrophy, progressive supranuclear palsy, vascular dementia, and frontotemporal dementia. The area under the receiver operating characteristic curve was 0.987 at a cluster discriminatory heart-to-mediastinum ratio threshold of 1.77. This threshold yielded 94% sensitivity and 91% specificity for the discrimination of these diagnostic clusters. 123I-metaiodobenzylguanidine cardiac scintigraphy can accurately distinguish between 2 movement disorders, Parkinson's disease and multiple system atrophy, and between 2 common causes of dementia, Alzheimer's disease and dementia with Lewy bodies.

Original languageEnglish (US)
Pages (from-to)1218-1224
Number of pages7
JournalMovement Disorders
Volume26
Issue number7
DOIs
StatePublished - Jun 2011

Fingerprint

3-Iodobenzylguanidine
Lewy Bodies
Radionuclide Imaging
Parkinson Disease
Meta-Analysis
Lewy Body Disease
Multiple System Atrophy
Alzheimer Disease
Progressive Supranuclear Palsy
Dementia
Movement Disorders
Mediastinum
REM Sleep Behavior Disorder
Frontotemporal Dementia
Vascular Dementia
Parkinsonian Disorders
ROC Curve
Sensitivity and Specificity

Keywords

  • Alzheimer's disease
  • Dementia with Lewy bodies
  • Multiple system atrophy
  • Parasomnias
  • Parkinson's disease

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Medicine(all)

Cite this

Meta-analysis of 123I-MIBG cardiac scintigraphy for the diagnosis of Lewy body-related disorders. / King, Alisha E.; Mintz, Jim; Royall, Donald R.

In: Movement Disorders, Vol. 26, No. 7, 06.2011, p. 1218-1224.

Research output: Contribution to journalArticle

@article{eb209517168e45618573ad38705d971d,
title = "Meta-analysis of 123I-MIBG cardiac scintigraphy for the diagnosis of Lewy body-related disorders",
abstract = "Patients with parkinsonism pose a diagnostic challenge. Parkinson's disease may be difficult to distinguish from multiple system atrophy and progressive supranuclear palsy, whereas Parkinson's disease and dementia with Lewy bodies can be difficult to distinguish from Alzheimer's disease and other dementias. A number of studies have found diminished cardiac 123I-metaiodobenzylguanidine uptake in Lewy body-related conditions (Parkinson's disease and Lewy body dementia). In 2005, the Dementia With Lewy Bodies Consortium considered 123I-metaiodobenzylguanidine cardiac scintigraphy a {"}supportive{"} diagnostic feature, based on limited evidence. We report a meta-analysis of the literature and an assessment of the utility of 123I-metaiodobenzylguanidine for the diagnosis of dementia with Lewy bodies and Parkinson's disease. A search was conducted of articles published between 1950 and June 2010. Forty-six studies involving neuropsychiatric and movement disorders, comprising 2680 subjects, were included in the analysis. A mixed-effects regression model was used to analyze the delayed mean heart-to-mediastinum ratio of 123I-metaiodobenzylguanidine uptake. 123I-metaiodobenzylguanidine cardiac scintigraphy sensitively detected and specifically distinguished 2 diagnostic clusters: (1) Parkinson's disease, dementia with Lewy bodies, and rapid eye movement sleep behavior disorder; and (2) normal controls and patients with Alzheimer's disease, multiple system atrophy, progressive supranuclear palsy, vascular dementia, and frontotemporal dementia. The area under the receiver operating characteristic curve was 0.987 at a cluster discriminatory heart-to-mediastinum ratio threshold of 1.77. This threshold yielded 94{\%} sensitivity and 91{\%} specificity for the discrimination of these diagnostic clusters. 123I-metaiodobenzylguanidine cardiac scintigraphy can accurately distinguish between 2 movement disorders, Parkinson's disease and multiple system atrophy, and between 2 common causes of dementia, Alzheimer's disease and dementia with Lewy bodies.",
keywords = "Alzheimer's disease, Dementia with Lewy bodies, Multiple system atrophy, Parasomnias, Parkinson's disease",
author = "King, {Alisha E.} and Jim Mintz and Royall, {Donald R}",
year = "2011",
month = "6",
doi = "10.1002/mds.23659",
language = "English (US)",
volume = "26",
pages = "1218--1224",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - Meta-analysis of 123I-MIBG cardiac scintigraphy for the diagnosis of Lewy body-related disorders

AU - King, Alisha E.

AU - Mintz, Jim

AU - Royall, Donald R

PY - 2011/6

Y1 - 2011/6

N2 - Patients with parkinsonism pose a diagnostic challenge. Parkinson's disease may be difficult to distinguish from multiple system atrophy and progressive supranuclear palsy, whereas Parkinson's disease and dementia with Lewy bodies can be difficult to distinguish from Alzheimer's disease and other dementias. A number of studies have found diminished cardiac 123I-metaiodobenzylguanidine uptake in Lewy body-related conditions (Parkinson's disease and Lewy body dementia). In 2005, the Dementia With Lewy Bodies Consortium considered 123I-metaiodobenzylguanidine cardiac scintigraphy a "supportive" diagnostic feature, based on limited evidence. We report a meta-analysis of the literature and an assessment of the utility of 123I-metaiodobenzylguanidine for the diagnosis of dementia with Lewy bodies and Parkinson's disease. A search was conducted of articles published between 1950 and June 2010. Forty-six studies involving neuropsychiatric and movement disorders, comprising 2680 subjects, were included in the analysis. A mixed-effects regression model was used to analyze the delayed mean heart-to-mediastinum ratio of 123I-metaiodobenzylguanidine uptake. 123I-metaiodobenzylguanidine cardiac scintigraphy sensitively detected and specifically distinguished 2 diagnostic clusters: (1) Parkinson's disease, dementia with Lewy bodies, and rapid eye movement sleep behavior disorder; and (2) normal controls and patients with Alzheimer's disease, multiple system atrophy, progressive supranuclear palsy, vascular dementia, and frontotemporal dementia. The area under the receiver operating characteristic curve was 0.987 at a cluster discriminatory heart-to-mediastinum ratio threshold of 1.77. This threshold yielded 94% sensitivity and 91% specificity for the discrimination of these diagnostic clusters. 123I-metaiodobenzylguanidine cardiac scintigraphy can accurately distinguish between 2 movement disorders, Parkinson's disease and multiple system atrophy, and between 2 common causes of dementia, Alzheimer's disease and dementia with Lewy bodies.

AB - Patients with parkinsonism pose a diagnostic challenge. Parkinson's disease may be difficult to distinguish from multiple system atrophy and progressive supranuclear palsy, whereas Parkinson's disease and dementia with Lewy bodies can be difficult to distinguish from Alzheimer's disease and other dementias. A number of studies have found diminished cardiac 123I-metaiodobenzylguanidine uptake in Lewy body-related conditions (Parkinson's disease and Lewy body dementia). In 2005, the Dementia With Lewy Bodies Consortium considered 123I-metaiodobenzylguanidine cardiac scintigraphy a "supportive" diagnostic feature, based on limited evidence. We report a meta-analysis of the literature and an assessment of the utility of 123I-metaiodobenzylguanidine for the diagnosis of dementia with Lewy bodies and Parkinson's disease. A search was conducted of articles published between 1950 and June 2010. Forty-six studies involving neuropsychiatric and movement disorders, comprising 2680 subjects, were included in the analysis. A mixed-effects regression model was used to analyze the delayed mean heart-to-mediastinum ratio of 123I-metaiodobenzylguanidine uptake. 123I-metaiodobenzylguanidine cardiac scintigraphy sensitively detected and specifically distinguished 2 diagnostic clusters: (1) Parkinson's disease, dementia with Lewy bodies, and rapid eye movement sleep behavior disorder; and (2) normal controls and patients with Alzheimer's disease, multiple system atrophy, progressive supranuclear palsy, vascular dementia, and frontotemporal dementia. The area under the receiver operating characteristic curve was 0.987 at a cluster discriminatory heart-to-mediastinum ratio threshold of 1.77. This threshold yielded 94% sensitivity and 91% specificity for the discrimination of these diagnostic clusters. 123I-metaiodobenzylguanidine cardiac scintigraphy can accurately distinguish between 2 movement disorders, Parkinson's disease and multiple system atrophy, and between 2 common causes of dementia, Alzheimer's disease and dementia with Lewy bodies.

KW - Alzheimer's disease

KW - Dementia with Lewy bodies

KW - Multiple system atrophy

KW - Parasomnias

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=79959366791&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959366791&partnerID=8YFLogxK

U2 - 10.1002/mds.23659

DO - 10.1002/mds.23659

M3 - Article

C2 - 21480373

AN - SCOPUS:79959366791

VL - 26

SP - 1218

EP - 1224

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 7

ER -